Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

iHOMA2 screenshotiHOMA2 is an interactive, 23-variable, HOmeostatic Model of Assessment with the baseline default characteristics of the HOMA2 computer model of fasting insulin:glucose interaction. 

iHOMA2 enables the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments to be modified using simple visual analogue controls. The model can be used to evaluate therapeutic agents and predict effects on fasting glucose and insulin and on beta cell function and insulin sensitivity. 


Download iHOMA2

 

The downloadable iHOMA2 program is implemented in Java and should work on all operating systems (requires Java). In this version you can copy and paste large amounts of data between iHOMA2 , Excel, SPSS etc. 

iHOMA2 is free to use for academic and non-commercial purposes.  If you wish to use it commercially please contact .

iHOMA2 has been developed by NR Hill, JC Levy and DR Matthews. © University of Oxford.

General disclaimer

This software is provided by the copyright holders and contributors "as is" and any express or implied warranties, including, but not limited to, the implied warranties of merchantability and fitness for a particular purpose are disclaimed. In no event shall the copyright owner or contributors be liable for any direct, indirect, incidental, special, exemplary, or consequential damages (including, but not limited to, procurement of substitute goods or services; loss of use, data, or profits; or business interruption) however caused and on any theory of liability, whether in contract, strict liability, or tort (including negligence or otherwise) arising in any way out of the use of this software, even if advised of the possibility of such damage. By using this software you agree to these terms. 

In this section

Keep informed

For the latest news and updates, sign up for our newsletter.

Sign up